Teva’s one-time blockbuster-to-be — and now recurring embarrassment — laquinimod fails yet again, this time for Huntington’s

Teva’s one-time blockbuster-to-be — and now recurring embarrassment — laquinimod fails yet again, this time for Huntington’s

Source: 
Endpoints
snippet: 

Teva has added yet another critical failure for laquinimod, which may finally be put on the chopping block.

The company’s partners at Active Biotech $ACTI announced that their Phase II study for Huntington’s disease failed, which comes on top of multiple failures in multiple sclerosis.